The study aimed to assess the diagnostic efficacy of S23PSA density (S23PSAD) and to compare it with traditional indicators, such as total PSA (tPSA) and PSA density (PSAD), as well as with MRI results in evaluating clinically significant cases of prostate cancer. Here, PROS1 is linked to prostate carcinoma.